Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

1.

Developing in vitro models of human ductal carcinoma in situ from primary tissue explants.

Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF.

Breast Cancer Res Treat. 2015 Aug 18. [Epub ahead of print]

PMID:
26283301
2.

A Comparison of Breast Cancer Multianalyte Assays With Algorithmic Analyses (MAAA) for Their Net Predictive/Prognostic Value.

Dabbs DJ.

Clin Adv Hematol Oncol. 2015 Jun;13(6 Suppl 6):14-25. No abstract available.

PMID:
26191942
3.

Molecular drivers of lobular carcinoma in situ.

Logan GJ, Dabbs DJ, Lucas PC, Jankowitz RC, Brown DD, Clark BZ, Oesterreich S, McAuliffe PF.

Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5.

4.

Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.

Li Z, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2015 Mar;143(3):451-8. doi: 10.1309/AJCPKIVVW4OBPX6I.

PMID:
25696805
5.

Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status.

Gloyeske NC, Woodard AH, Elishaev E, Yu J, Clark BZ, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):202-8. doi: 10.1097/PAI.0000000000000076.

PMID:
25356941
6.

Simultaneous breast and axillary recurrence in a patient with a history of breast cancer and ipsilateral upper extremity melanoma: challenges in diagnosis and management.

Ross M, Hadzikadic Gusic L, Dabbs DJ, Kelley J, Diego E.

Tumori. 2014 Jul-Aug;100(4):136e-9e. doi: 10.1700/1636.17928.

PMID:
25296604
7.

Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.

Clark BZ, Beriwal S, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 Jul;142(1):64-71. doi: 10.1309/AJCP8H2VBDSCIOBF.

8.
9.

Low ER+ breast cancer: Is this a distinct group?

Gloyeske NC, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.

10.

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S.

Cancer Res. 2014 Mar 1;74(5):1463-74. doi: 10.1158/0008-5472.CAN-13-2779. Epub 2014 Jan 14.

11.

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

Gao FF, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2014 Jan;141(1):102-10. doi: 10.1309/AJCP6CXS8OSRHXIR.

12.

Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.

Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR, Palacios J, Rakha E, Richardson AL, Schmitt FC, Tan PH, Tse GM, Vincent-Salomon A, Ellis IO, Badve S, Reis-Filho JS.

Am J Surg Pathol. 2013 Jul;37(7):e1-11. doi: 10.1097/PAS.0b013e3182918a2b. Review.

PMID:
23759937
13.

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.

Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargava R.

Mod Pathol. 2013 May;26(5):658-64. doi: 10.1038/modpathol.2013.36. Epub 2013 Mar 15.

14.

Cancer of unknown primary origin: using ancillary techniques with caution.

Bhargava R, Dabbs DJ.

J Clin Oncol. 2013 Apr 10;31(11):1478-9. doi: 10.1200/JCO.2012.46.9056. Epub 2013 Feb 25. No abstract available.

15.

Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.

Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R.

Int J Gynecol Cancer. 2013 Feb;23(2):380-4. doi: 10.1097/IGC.0b013e31825cc8ee.

PMID:
23318908
16.

Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems.

Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S.

Steroids. 2013 Jun;78(6):568-75. doi: 10.1016/j.steroids.2012.11.002. Epub 2012 Nov 21. Review.

PMID:
23178159
17.

Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Li X, Kanbour-Shakir A, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):420-5. doi: 10.1097/PAI.0b013e318273c1cc.

PMID:
23165332
18.

Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.

Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, Chivukula M, Trucco GA, Bhargava R.

Am J Clin Pathol. 2012 Dec;138(6):796-802. doi: 10.1309/AJCP6DKRND5CKVDD.

19.

Commonly encountered dilemmas in breast cancer reporting and staging.

Adams AL, Dabbs DJ.

Semin Diagn Pathol. 2012 Aug;29(3):109-15. doi: 10.1053/j.semdp.2011.08.003. Review.

PMID:
23062418
20.

Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.

Clark BZ, Dabbs DJ, Cooper KL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):287-91. doi: 10.1097/PAI.0b013e31826f80c9.

PMID:
23060300
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk